The #1 Prescribed biologic* By Allergists and ENTs3
>1 MILLION PATIENTS TREATED WITH
DUPIXENT ACROSS INDICATIONS
WORLDWIDE1,4,a,b
* monoclonal antibody
aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US), representing ~90% of patients. Data through August 2024.4
bNew adult and pediatric patients (6+ months of age) with uncontrolled moderate-to-severe atopic dermatitis; new adult and pediatric patients (6+ years of age) with moderate-to-severe asthma (eosinophilic/oral corticosteroid dependent); new adult patients with inadequately controlled CRSwNP; new adult and pediatric patients (1+ year of age), weighing at least 15 kg, with EoE; and new adult patients with PN.1,4
WITH DUPIXENT, AIM TO BREAK THE
CYCLE
OF RECURRENCE IN CRSwNP1,2:
SOURCES OF
TYPE 2 INFLAMMATION
- DUPIXENT targets IL‑4 and
IL‑13 signaling, two of the key drivers of type 2 inflammation and its disease burdens1,5,6,c
cThe mechanism of dupilumab action has not been definitively established.1
SYMPTOMS
- Rapid results at Day 3 for Loss of Smelld and Day 2 for nasal congestion7,e
Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.7,8
- Sustained results through
Week 521,2,f-i
Data in adults.1,2,7,9
CONTROL
- 83% fewer patients required surgery1
- 74% fewer patients required systemic steroids1
76% fewer patients required surgery and/or systemic steroids.1,j Individually, these were not multiplicity-adjusted endpoints.1,2 Data in adults.1
Phase 3 Clinical Trials in Adults: Coprimary Endpoints, LSM difference, DUPIXENT 300 mg
Q2W + INCS vs placebo + INCS at Week 241,2
SINUS-24 (DUPIXENT n=143, placebo n=133): NC score: -0.89 (95% CI: -1.07, -0.71).
NPS: -2.06 (95% CI: -2.43, -1.69).
SINUS-52 (DUPIXENT n=295, placebo n=153): NC score: -0.87 (95% CI: -1.03, -0.71).
NPS: -1.80 (95% CI: -2.10, -1.51).
dLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02). Patient-reported outcome.7-9
eLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).7,9
fLoS at Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98 (95% CI: -1.15, -0.81) (P<0.0001).2
gNC at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (P<0.0001).1,2
hLoS at Week 52 in SINUS-52 (other secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.10 (95% CI: -1.31, -0.89).1,2
iNC at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (P<0.0001).2
jIn SINUS-24 and SINUS-52, DUPIXENT (Day 0: n=438; Week 24: n=376; Week 52: n=100); placebo (Day 0: n=286; Week 24: n=187; Week 52: n=61).1
Loss of Smell (LoS) score (range 0-3): reduced score indicates improvement.1
Nasal congestion/obstruction (NC) score (range 0-3): reduced score indicates improvement.1
Nasal polyp score (NPS) (range 0-4 for each nostril, range 0-8 in total): reduced score indicates improvement.1
EoE, eosinophilic esophagitis; INCS, intranasal corticosteroid; LSM, least squares mean; MOA, mechanism of action; PN, prurigo nodularis; Q2W, once every 2 weeks.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance treatment in adults with inadequately controlled CRSwNP.1
Patient portrayal.
Multiple Administration
Options
Offer your adult and pediatric patients 12 years and older flexible administration: at home or in office1
Safety
Data
View safety data across clinical trials
Support can make all the difference. DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
Check Formulary Status in Your Area
See the coverage status for DUPIXENT, prior authorization, and step edit information by ZIP code.
Contact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your product-related questions.